Search Medical Condition
Please enter condition
Please choose location

Scranton, Pennsylvania Clinical Trials

A listing of Scranton, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (62) clinical trials

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

OBJECTIVES Primary To compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer. Secondary To compare whether the addition of one year of ...

Phase

0.0 miles

Learn More »

Tamoxifen Citrate Letrozole Anastrozole or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

PRIMARY OBJECTIVES: I. To determine the effect of chemotherapy in patients with node positive breast cancer who do not have high recurrence scores (RS) by Oncotype DX. SECONDARY OBJECTIVES: I. To compare overall survival (OS), distant disease-free survival (DDFS) and local disease-free interval (LDFI) by receipt of chemotherapy or not ...

Phase

0.0 miles

Learn More »

Ixazomib Citrate Lenalidomide Dexamethasone and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

This phase III randomized clinical trial was designed to assess the impact of the addition of ixazomib, lenalidomide, and dexamethasone to zoledronic acid the multiple myeloma progression rate at 5 years. A dynamic allocation procedure will be used to allocate an equal number of patients to each of the treatment ...

Phase

0.7 miles

Learn More »

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

0.7 miles

Learn More »

AdaptResponse Clinical Trial

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Phase N/A

0.7 miles

Learn More »

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

The primary aim of this study is to determine the value of regorafenib in improving DFS. The secondary aims are to evaluate the dose tolerance and long term toxicity of two years of regorafenib following standard adjuvant therapy, and to evaluate the effect of the use of regorafenib in overall ...

Phase

0.7 miles

Learn More »

CA-IX p16 Proliferative Markers and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

PRIMARY OBJECTIVES: I. To examine CA-IX, p16, Ki-67, and mini-chromosome maintenance complex component 2 (MCM2) expression in liquid-based cytology (LBC) specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in North America with a cytologic diagnosis of atypical glandular cells (AGC) ...

Phase N/A

0.7 miles

Learn More »

Cetuximab Cisplatin Fluorouracil and Radiation Therapy in Treating Patients With Stage I Stage II or Stage III Anal Cancer

OBJECTIVES: Primary - Determine whether the addition of cetuximab to combined modality therapy (CMT) comprising cisplatin, fluorouracil, and radiotherapy reduces the local failure rate by ≥ 50% at 3 years (compared with historical data) in immunocompetent patients with stage I-IIIB invasive anal carcinoma. Secondary - Determine objective response rate (complete ...

Phase

0.7 miles

Learn More »

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients treated with durvalumab (MEDI4736) plus tremelimumab. SECONDARY OBJECTIVES: I. To estimate the duration of response (DoR) among patients who achieve a complete response (CR) ...

Phase

0.7 miles

Learn More »

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II III or IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine if women who are disease-free after successfully completing primary and potential consolidation/maintenance, therapy for stage II-IV ovarian, fallopian tube or primary peritoneal cancer and who are randomized to a healthy lifestyle intervention, will have significantly increased progression-free survival compared to similar women who are randomized ...

Phase

0.7 miles

Learn More »